- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02869035
Treatment Outcome in Major Depressive Disorder
Predicting Treatment Outcome in Major Depressive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study population and study program:
Patients will be recruited through a unique new central referral site for "depression packages" in The Mental Health Services in the Capital Region of Denmark. 100 patients with MDD, 18-65 years of age, with moderate to severe single or recurrent episode of MDD (Hamilton 17 item (HAMD-17) score > 17) will be recruited through this portal. All diagnoses will be confirmed by a specialist in psychiatry.
Before initiation of pharmacological antidepressant treatment with escitalopram, patients will receive baseline examinations as follows: 1) 5-HT4R imaging with 11C-SB207145 PET-scan, 2) EEG examinations, 3) structural MRI, 4) functional MRI , 5) neuropsychological testing, 6) peripheral markers of immune-active cell responses, oxidative stress, cortisol-levels, RNA, genotypes and epigenetic factors will be measured in urine, saliva and peripheral blood at baseline and across the study period. Repeated measures across the study period include: 7) psychometrics by using self-reported questionnaires covering trait and state, including mental distress related to depression and other psychopathology, 8) neuropsychological examinations as well as 9) clinical follow-up with interview based ratings of mental status.
Patients will be treated with escitalopram at flexible doses of 10-20 mg/day adjusted depending on effects and side effects, and participate in clinical follow-up sessions at week 1, 2, 4 and 8. Patients with no response to escitalopram after 4 weeks will be shifted to a secondary pharmacological treatment (duloxetine). A final visit to determine longer-term clinical outcome will be performed at week 12. Compliance, side-effects to antidepressant treatment, and depressive symptoms will be monitored at each follow-up session.
The Hamilton 6 items (HAMD-6) subscale has recently shown to be more sensitive to antidepressant response (Østergaard et al), and will be used to identify treatment response in patients. Patients with > 50 % reduction in HAMD-6 after 4 weeks will be defined as early responders, and those with additional < 5 points on the HAMD-6 scale after 8 weeks will be considered in remission. Patients with >25% response at week 4 and < 50% reduction in HAMD-6 after full intervention will be considered non-responders. The assessment program including brain imaging with PET 11C-SB207145 will be conducted before drug intervention is initiated and, depending on treatment outcome, again after 8 weeks of antidepressant treatment in 20 patients in remission (remitters) and 20 non-responding patients (non-responders).
UPDATE: As per April 3, 2017 the rescanned group has been expanded to include various response patterns in order to capture rescan data from patients on a spectrum from poor to excellent treatment response, since out of the first 17 included patients only 1 patient fulfilled the non-responder criterion defined above. Accordingly, the clinical outcome parameter in the context will be changes in HAM-D6 from baseline at week 8.
Healthy controls:
From previous studies conducted at the Neurobiological Research Unit, there is access to brain imaging data and baseline PET-SB207145 brain images among healthy controls as well as an associated biobank with stored blood specimens. During the trial, additional healthy controls will be included and will receive baseline examinations and repeated neuropsychological testing after 12 weeks.
Hypotheses:
- 5-HT4R binding (as imaged by 11C-SB207145 PET) before treatment will predict antidepressant treatment outcome (remission vs non-response) in depressed patients; higher binding at baseline is hypothesized to be associated with a better treatment outcome. Likewise, secondary, 5-HT4R binding (as imaged by 11C-SB207145 PET) before treatment is expected to be associated with the magnitude of change from baseline in Hamilton score (HAMD-6) at 8 weeks.
- Remitters will display a greater reduction in 5-HT4R binding (as imaged by 11C-SB207145 PET) after antidepressant treatment relative to non-responders.
- Patients with MDD will have a higher 5-HT4R binding (as imaged by 11C-SB207145 PET) relative to healthy controls.
- High amygdala reactivity in an "emotional faces" fMRI paradigm before treatment predicts remission in response to antidepressant treatment.
- Amygdala response to exposure to negative emotional faces (fear and anger) and cerebral 5-HT4R binding is expected to be associated, both in cross-sectional comparison before treatment and with regard to longitudinal changes (changes from baseline).
- In resting state fMRI (rsfMRI), we expect that changes from baseline in a functional network centered around dorsomedial prefrontal cortex and other networks centered around anterior cingulate cortex and posterior cingulate cortex (default mode network) respectively will predict treatment outcome.
- Low activity in a brain network engaged in reward processing (as assessed by fMRI) will predict antidepressant treatment response (i.e. positive association between low activity and remitter- relative to non-responder group) both in cross-sectional comparison before treatment and with regard to longitudinal changes (changes from baseline).
- We expect reduced evoked gamma-activity measured with EEG and "Event-related-potentials" (ERP) in MDD patients compared to controls.
- Using EEG/ERP, we expect reduced alpha and theta cordance and higher theta band activity among remitters measured at baseline.
- Higher levels of systemic inflammation will predict poor cognitive function at baseline, and a poor antidepressant treatment outcome.
- A blunted cortisol awakening response (CAR) at baseline will predict a positive antidepressant treatment outcome.
- Restored HPA-axis dynamics (increased CAR compared to baseline) at week 8 will be associated with a positive treatment outcome.
- There will be a significant association between functional networks found by EEG and fMRI, both at baseline and as contrast between remitters and non-responders after 8 weeks.
- Hippocampal volume will predict treatment outcome.
- Patients with a low 5-HT4R binding (as imaged by 11C-SB207145 PET) at baseline before treatment will have a lower libido relative to patients with a high binding.
- Patients who respond to antidepressant treatment with the most pronounced changes in 5-HT4R binding (as imaged by 11C-SB207145) will experience a larger degree of sexual side-effects; i.e., the magnitude of 5-HT4R binding changes from baseline will be positively associated with the degree of sexual side-effects.
- Childhood abuse (defined by a composite measure of early life stress questionnaires) and anxious depression (defined as anxiety/somatization factor score in HAMD-17 > 7) predicts poor antidepressant treatment outcome.
- We expect urinary markers of oxidatively generated DNA/RNA damage to increase more in responders than in non-responders.
- With an exploratory approach it will be possible to identify a set of predictors of antidepressant treatment outcome. This explorative analysis includes genetics, epigenetics, peripheral and central neurobiological characteristics, neuropsychology testing outcomes, psychometry including self-reported mental distress, both cross-sectional at baseline and as longitudinal measures.
Ethical Aspects:
The study protocol complies with the Declaration of Helsinki II and approval by all relevant authorities will be obtained before initiation. All human volunteers will receive oral and written information about the given study and provide written informed consent before enrolment. The trial is monitored by a Good Clinical Practise unit for the relevant domains.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Neurobiology Research Unit, Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate to severe depression
- Age 18-65 years
- No previous antidepressant treatment the last 2 months
- Informed and signed consent
Exclusion Criteria:
- More than one previous attempt with antidepressant drugs
- Duration of current depression more than 2 years
- Current or previous psychiatric severe co-morbidity
- Acute suicidal ideation
- Psychotic
- Previous non-response to Selective Serotonin Reuptake Inhibitor (SSRI)
- Contraindication for SSRI treatment
- More suitable with treatment of alternative anti-depressive drug.
- Severe somatic co-morbidity
- Somatic medicine that can influence the trial
- Contraindications for MR-scanning
- Previous exposure to radioactivity > 10 milli sievert (mSv) within the last year
- Alcohol or drug abuse
- Previous severe head trauma
- Pregnancy
- Breast-feeding
- Insufficient Danish skills
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment of MDD patients
Treatment of MDD patients with escitalopram
|
Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks.
If no response after 4 weeks; shift to duloxetine arm.
|
No Intervention: Healthy controls
No treatment.
|
|
Experimental: Shift of treatment for MDD patients
Treatment of MDD patients with duloxetine
|
Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Binary treatment outcome in terms of remission from depression.
Time Frame: Baseline to clinical follow-up at 8 weeks after antidepressant treatment.
|
Treatment outcome defined as changes in HAMD-6 score after antidepressant treatment (remitters and non-responders as previously defined).
|
Baseline to clinical follow-up at 8 weeks after antidepressant treatment.
|
Baseline cerebral 5-HT4R binding as imaged by 11C-SB207145 PET.
Time Frame: Baseline.
|
Latent variable construct of 5-HT4R level based on quantification of 5-HT4R binding in primary volumes of interest; neocortex, nucleus caudatus, putamen and hippocampus.
Assessed in depressed patients and healthy controls.
|
Baseline.
|
Changes from baseline in cerebral 5-HT4R binding as imaged by 11C-SB207145 PET
Time Frame: Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Difference in latent variable construct of 5-HT4R level based on quantification of 5-HT4R binding in primary volumes of interest; neocortex, nucleus caudatus, putamen and hippocampus.
Measured in remitters and non-responders.
|
Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Baseline hippocampus volume
Time Frame: Baseline.
|
Structural MRI scan in depressed patients and healthy controls.
|
Baseline.
|
Changes from baseline in hippocampus volume.
Time Frame: Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Structural MRI in remitters and non-responders.
|
Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Baseline fMRI BOLD response to an emotional faces paradigm
Time Frame: Baseline
|
fMRI (BOLD response) based assessment of brain activity to emotionally salient, relative to neutral, stimuli.
|
Baseline
|
Changes from baseline in fMRI BOLD response to an emotional faces paradigm
Time Frame: Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
fMRI (BOLD response) based assessment of brain activity to emotionally salient, relative to neutral, stimuli.
|
Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Baseline fMRI BOLD response to reward paradigm.
Time Frame: Baseline
|
fMRI (BOLD response) based assessment of brain activity in response to reward, relative to non-reward, stimuli.
|
Baseline
|
Changes from baseline in fMRI BOLD response to reward paradigm
Time Frame: Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
fMRI (BOLD response) based assessment of brain activity in response to reward, relative to non-reward, stimuli.
|
Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Baseline rsfMRI based spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)
Time Frame: Baseline
|
Assessed with rsfMRI scan in the resting state, i.e. non-goal oriented spontaneous thought and awake.
|
Baseline
|
Changes from baseline in rsfMRI spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)
Time Frame: Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Assessed with rsfMRI scan in the resting state, i.e. non-goal oriented spontaneous thought and awake.
|
Baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Sexual function in depression
Time Frame: Baseline
|
Assessed with scores of self reported sexual function questionnaires in depressed patients and healthy controls.
|
Baseline
|
Changes in sexual function
Time Frame: Baseline to clinical follow-up at 8 or 12 weeks after antidepressant treatment, and baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Questionnaire-based self-reported sexual function in remitters and non-responders
|
Baseline to clinical follow-up at 8 or 12 weeks after antidepressant treatment, and baseline to follow-up scan at 8 weeks after antidepressant treatment.
|
Baseline EEG including event related potentials (ERP)
Time Frame: Baseline
|
Assessment of evoked gamma activity, alpha and theta cordance band activity in depressed patients and healthy controls.
|
Baseline
|
Changes in EEG including event related potentials (ERP)
Time Frame: Baseline to follow-up examination at 8 weeks after antidepressant treatment.
|
Assessment of evoked gamma activity, alpha and theta cordance band activity in remitters and non-responders.
|
Baseline to follow-up examination at 8 weeks after antidepressant treatment.
|
Cortisol awakening response
Time Frame: Baseline
|
Cortisol changes in response to awakening as measured in saliva from 0 to 60 minutes after awakening in depressed patients and healthy controls.
|
Baseline
|
Changes in cortisol awakening response (HPA-axis dynamics)
Time Frame: Baseline and follow-up examination at 8 weeks after antidepressant treatment.
|
Measured in remitters and non-responders.
|
Baseline and follow-up examination at 8 weeks after antidepressant treatment.
|
Systemic inflammation peripheral blood hsCRP and immunoactive cytokines
Time Frame: Baseline and follow-up examination at 8 weeks after antidepressant treatment.
|
Measured with peripheral blood markers in plasma by high-sensitivity (hs) methods.
|
Baseline and follow-up examination at 8 weeks after antidepressant treatment.
|
Changes in systemic inflammation peripheral blood hsCRP and immunoactive cytokines
Time Frame: Baseline and follow-up examination at 8 weeks after antidepressant treatment.
|
Measured with peripheral blood markers in plasma by high-sensitivity (hs) methods.
|
Baseline and follow-up examination at 8 weeks after antidepressant treatment.
|
Systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine
Time Frame: Baseline
|
8-oxodG and 8-oxoGuo measured with mass spectrometry in spot-urine and normalized to urinary creatinine, in depressed patients and healthy controls.
|
Baseline
|
Changes in systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine
Time Frame: Baseline and follow-up examinations at 8 weeks after antidepressant treatment.
|
8-oxodG and 8-oxoGuo measured with mass spectrometry in spot-urine and normalized to urinary creatinine, in remitters and non-responders.
|
Baseline and follow-up examinations at 8 weeks after antidepressant treatment.
|
Early life Stress
Time Frame: Baseline
|
Self-reported early life stress with the Children Abuse and Trauma Scale (CATS) questionnaire.
|
Baseline
|
Performance on Verbal Affective Memory Tasks (VAMT-26).
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Performance on Moral Judgement Task
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Performance on Letter-Number Sequence Task.
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in HAMD-6 score
Time Frame: Baseline to follow-up at 8 and 12 weeks
|
Score indexing changes in severity of the depressed state
|
Baseline to follow-up at 8 and 12 weeks
|
HAMD-6 score after 8 and 12 weeks of antidepressant treatment
Time Frame: Week 8 and 12 of treatment period
|
Score indexing severity of the depressed state
|
Week 8 and 12 of treatment period
|
Regional 5-HT4R binding
Time Frame: Measured at baseline and after 8 weeks of antidepressant treatment.
|
Measurement of 5-HT4R binding in (a) striatum (caudate nuclei and putamen), (b) a pooled limbic region (amygdala, hippocampus, thalamus, anterior- and posterior cingulate cortex,) (c) a pooled neocortex region (parietal cortex, occipital cortex, lateral temporal cortex, insula, orbito-frontal and lateral-frontal cortex).
|
Measured at baseline and after 8 weeks of antidepressant treatment.
|
Sexual side-effects from antidepressant treatment
Time Frame: 8 weeks of antidepressant treatment
|
Perceived side effects from self reported questionnaires
|
8 weeks of antidepressant treatment
|
Baseline latent variable construct of self-reported mental state
Time Frame: Baseline
|
Composed by latent variable structural equation modelling of self-reported mental state from questionnaires score of: Becks Depression Inventory -II (BDI-II), Perceived Stress Scale (PSS), Snaith-Hamilton Pleasure Scale (SHAPS), Rumination Response Scale (RRS), Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Distress Assessment 10 item (GAD-10), Activity level, Profile of Mood States (POMS), Visual Analogue Scale for mental distress (VAS) and Brief symptom Inventory-53 item (BSI-53)) in depressed patients and healthy controls.
|
Baseline
|
Baseline self reported family history of mood disorders
Time Frame: Baseline
|
Family History Assessment Module (OS-FHAM) in depressed patients and healthy controls.
|
Baseline
|
Changes from baseline in self-reported mental state questionnaire-based latent variable construct
Time Frame: At baseline and repeated across the study period to last follow-up after 12 weeks of antidepressant treatment.
|
Composed by latent variable structural equation modelling of changes from baseline in self-reported mental state from questionnaires score of: Becks Depression Inventory -II (BDI-II), Perceived Stress Scale (PSS), Snaith-Hamilton Pleasure Scale (SHAPS), Rumination Response Scale (RRS), Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Distress Assessment 10 item (GAD-10), Activity level, Profile of Mood States (POMS) and Brief symptom Inventory-53 item (BSI-53) in remitters and non-responders.
|
At baseline and repeated across the study period to last follow-up after 12 weeks of antidepressant treatment.
|
Total daily cortisol output
Time Frame: Baseline (before treatment)
|
Area under curve of 8 serial measures of salivary cortisol concentrations during an assessment day
|
Baseline (before treatment)
|
Changes in total daily cortisol output
Time Frame: Baseline (before treatment) to 8 weeks of antidepressant treatment
|
Difference in area under curve of 8 serial measures of salivary cortisol concentrations during an assessment day
|
Baseline (before treatment) to 8 weeks of antidepressant treatment
|
Parental bonding quality
Time Frame: Baseline
|
Self-reported parental bonding quality as assessed in baseline by parental bonding interview (PBI)
|
Baseline
|
5-HTTLPR genotype status
Time Frame: Baseline
|
5-HTTLPR genotype status (binary), i.e. high-expressing LALA vs low-expressing (S or LG) variants
|
Baseline
|
Epigenetic FK506-binding protein 51 (FKBP5) status at baseline
Time Frame: Baseline
|
Methylation of the FKBP5 gene
|
Baseline
|
Changes in epigenetic FKBP5 status from baseline
Time Frame: Baseline to 8 and 12 weeks of intervention
|
Changes in methylation status of the FKBP5 gene
|
Baseline to 8 and 12 weeks of intervention
|
Epigenetic 5-HTTLPR status at baseline
Time Frame: Baseline
|
Methylation status of the 5-HTTLPR gene
|
Baseline
|
Changes in epigenetic 5-HTTLPR status from baseline
Time Frame: Baseline to 8 and 12 weeks of intervention
|
Changes in methylation status of the 5-HTTLPR gene
|
Baseline to 8 and 12 weeks of intervention
|
Epigenetic spindle and kinetochore associated complex subunit 2 (SKA2) status at baseline
Time Frame: Baseline to 8 and 12 weeks of intervention
|
Methylation status of the SKA2 gene
|
Baseline to 8 and 12 weeks of intervention
|
Changes in epigenetic SKA2 status from baseline
Time Frame: Baseline to 8 and 12 weeks of intervention
|
Changes in methylation status of the SKA2 gene
|
Baseline to 8 and 12 weeks of intervention
|
Performance on Face and Eyes Emotion Recognition Task
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Performance on Intensity Morphing Task
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Performance on Social Information Preference Task
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Performance on Simple Reaction Time.
Time Frame: From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Differences between healthy controls and depressed patients at baseline and week 12 follow-up, as well as longitudinal alterations to treatment response in MDD patients.
|
From baseline to follow-up after 12 weeks of treatment with antidepressant treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gitte M Knudsen, MD,Prof., Neurobiology Research Unit
Publications and helpful links
General Publications
- Ostergaard SD, Bech P, Miskowiak KW. Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D(6)) as outcome measure. J Affect Disord. 2016 Jan 15;190:842-845. doi: 10.1016/j.jad.2014.10.047. Epub 2014 Nov 7.
- Dam VH, Stenbaek DS, Kohler-Forsberg K, Cheng Ip, Ozenne B, Sahakian BJ, Knudsen GM, Jorgensen MB, Frokjaer VG. Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study. Transl Psychiatry. 2022 Nov 8;12(1):468. doi: 10.1038/s41398-022-02240-1.
- Fisher PM, Ozenne B, Ganz M, Frokjaer VG, Dam VN, Penninx BW, Sankar A, Miskowiak K, Jensen PS, Knudsen GM, Jorgensen MB. Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study. J Psychopharmacol. 2022 May;36(5):626-636. doi: 10.1177/02698811221089035. Epub 2022 May 13.
- Ip CT, Olbrich S, Ganz M, Ozenne B, Kohler-Forsberg K, Dam VH, Beniczky S, Jorgensen MB, Frokjaer VG, Sogaard B, Christensen SR, Knudsen GM. Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study. Eur Neuropsychopharmacol. 2021 Aug;49:101-112. doi: 10.1016/j.euroneuro.2021.03.024. Epub 2021 Apr 25.
- Kohler-Forsberg K, Jorgensen A, Dam VH, Stenbaek DS, Fisher PM, Ip CT, Ganz M, Poulsen HE, Giraldi A, Ozenne B, Jorgensen MB, Knudsen GM, Frokjaer VG. Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol. Front Psychiatry. 2020 Jul 23;11:641. doi: 10.3389/fpsyt.2020.00641. eCollection 2020.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- MRI
- Oxidative stress
- Inflammation
- Anxiety
- PET
- MDD
- fMRI
- EEG
- Mental health
- Serotonin
- Psychometrics
- Escitalopram
- Sexual function
- Brain imaging
- Selective Serotonin Reuptake Inhibitor
- Social cognition
- ERP
- 5-HT4R
- Cortisol awakening response
- Prediction of treatment response
- 5-HTTLPR
- Early life stress
- Moderate depression
- Severe depression
- rsfMRI
- 11C-SB207145
- Affective cognition
- Cold cognition
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
- Citalopram
Other Study ID Numbers
- NP1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Escitalopram
-
First Affiliated Hospital of Zhejiang UniversityRecruitingAdolescent | Depressive DisorderChina
-
Perry RenshawTerminatedDepression | Substance Use | Dual DiagnosisUnited States
-
University of NebraskaRecruiting
-
Rigshospitalet, DenmarkUniversity of Cambridge; Lundbeck FoundationCompleted
-
Ryerson UniversityUnknownInsomnia | Major Depressive DisorderCanada
-
Centre Hospitalier Universitaire VaudoisNot yet recruitingPharmacogenetic Testing
-
Shanghai 7th People's HospitalNot yet recruitingDepressive Disorder, MajorChina
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Completed
-
Shanghai Mental Health CenterRecruiting
-
University of PennsylvaniaWashington University School of MedicineCompleted